• Contact Us

  • Pipeline
    Lynovex (NM001) Nylexa (NM002) Novexatin (NP213) NP339 NP432

  • Technology

  • Therapeutic Focus

  • About Us
    Board and Management Investors Corporate Social Responsibility

  • News and Events
  • Follow
  • Follow
  • Follow
  • News and Events
  • About Us
    • Board and Management
    • Investors
    • Corporate Social Responsibility
  • Therapeutic Focus
  • Technology
  • Pipeline
    • NM001 (Lynovex®)
    • NM002 (Nylexa®)
    • NP213 (Novexatin®)
    • NP339
    • NP432
  • Contact Us

News and Events

Just when we thought things were getting better…..

Dec 31, 2020

CARE CF 1 oral Lynovex clinical trial data published

Dec 29, 2020

NovaBiotics in the press

Dec 28, 2020

As world antimicrobial awareness week gets underway, our CEO shares her thoughts on the near-term outlook for antimicrobials: the economic case aligning with innovation

Nov 18, 2020

Why, in the current crisis we still need more effective, proven treatments for COVID-19

Nov 17, 2020

Appointment of Dr Malcolm Barratt-Johnson to the Board of NovaBiotics

Nov 10, 2020

The truth about why we need this COVID-19 treatment right now!

Oct 22, 2020

NovaBiotics secures £1m funding for COVID 19 project

Oct 16, 2020

OBE for NovaBiotics’ CEO in the Queen’s Birthday Honours List

Oct 12, 2020

“Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy” published today

Jul 7, 2020

Categories

Press Releases

Events

Archives

2020 

2019

NovaBiotics Ltd
Silverburn Crescent
Bridge of Don
Aberdeen
AB23 8EW, UK

Tel:+44 (0)1224 711377

Registered Company
No. SC272344

NovaBiotics Inc
One Boston Place,
Suite 2600,
Boston
MA, 02108

Tel:+1 866 259 4527

NovaBiotics
90 Upper George's Street,
Dun Laoghaire,
Co. Dublin,
A96 R8R9

Tel:+353 1 2712605

Registered Company
No. 642058

News and Events

About Us

Therapeutic Focus

Technology

Pipeline

Contact Us